Company news
Csl Limited (ASX:CSL) news
Every Csl Limited press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
World’s-First Battery-Powered Self-Unloading Bulk Carrier Now Operating in South Australia
August 26, 2026
CSL Results Presentation for FY2026
August 17, 2026
CSL Marks the Completion of the First Vessel in World-Leading Transhipment Fleet for Simandou Project
July 28, 2026
CSL Reports Positive Top-Line Phase 3b Results Supporting Planned Expanded Pediatric Filing for ANDEMBRY® (garadacimab-gxii) in Children ...
July 27, 2026
CSL Delivers World’s First Battery-Powered Self-Unloading Bulk Carrier to Support Adbri Operations
June 12, 2026
CSL Takes Delivery of MV CSL Kuleana, Advancing CSL International Pool Newbuild Program
June 3, 2026
CSL Canada Announces First Canadian Patient Receives HEMGENIX® (etranacogene dezaparvovec) Hemophilia B Gene Therapy in Ontario, Canada
May 20, 2026
Vaccine Adjuvant Market Set to Boom Rapidly, Witnessing Strong Growth Through 2033 | CSL Limited, Seppic
May 14, 2026
CSL : Seqirus Signs Long-Term Agreement with the Pan American Health Organization (PAHO) to Advance Pandemic Influenza Preparedness in La...
May 12, 2026
Interim CEO 90 Day Review and Financial Update
May 10, 2026
CSL Seqirus Signs Long-Term Agreement with The Pan American Health Organization to Advance Regional Influenza Protection in the Region of...
March 11, 2026
CSL : Seqirus Signs Long-Term Agreement with The Pan American Health Organization (PAHO) to Advance Regional Influenza Protection in the ...
March 10, 2026
CSL announces expansion of Illinois plasma therapy manufacturing facility
March 9, 2026
Canada and CSL Seqirus, a Global Leader in Influenza Vaccines, agree on new Pandemic Preparedness Contract
March 6, 2026
CSL : Canada and CSL Seqirus, a Global Leader in Influenza Vaccines, agree on new Pandemic Preparedness Contract
March 5, 2026
CSL : Neffy, adrenaline nasal spray, now approved to treat anaphylaxis in Australia
February 16, 2026
CSL Half Year Results Investor Presentation
February 10, 2026
CSL Statutory Accounts for the Half Year Ended 31 December
February 10, 2026
CSL Half Year Results Announcement
February 10, 2026
Paul McKenzie retires, Gordon Naylor appointed interim CEO
February 10, 2026
Deutsche Bank Appointed as Successor Depositary Bank for the American Depositary Receipt Program of CSL Limited
January 27, 2026
Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec...
December 7, 2025
CSL : to invest approximately $1.5b in U.S. to manufacture plasma-derived therapies
November 18, 2025
CSL Capital Markets Day
November 4, 2025
CSL : Seqirus and Vaccine Industrial Company sign landmark Memorandum of Understanding with Ministry of Health to localize manufacturing ...
October 30, 2025
CSL 2025 AGM Chair and CEO Speech and Presentation
October 27, 2025
CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering (ISPE)
October 26, 2025
Recent RWE Data Show Cell-Based Influenza Vaccines Offer 20% Greater Protection in the Prevention of Test-Confirmed Influenza in Pediatri...
October 21, 2025
CSL : Seqirus Presents Latest Research Across Leading Seasonal Influenza Vaccine Portfolio at ESWI 2025
October 17, 2025
CSL Behring Signs Letter of Intent with pan-Canadian Pharmaceutical Alliance (pCPA) for Public Reimbursement of HEMGENIX® (etranacogene d...
October 6, 2025
CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy
September 26, 2025
VarmX Partners With CSL in a Strategic Collaboration and Option Agreement to Develop Novel Investigational Coagulation Treatment
September 16, 2025
CSL partners on new coagulation treatment
September 15, 2025
CSL FY25 Results and Major Strategic Initiatives
August 18, 2025
CSL Results Presentation
August 18, 2025
CSL Statutory Accounts for FY2025
August 18, 2025
Health Canada Has Authorized CSL's ANDEMBRY(R) (garadacimab) as Once-Monthly Treatment for Hereditary Angioedema (HAE)
August 12, 2025
Health Canada Has Authorized CSL's ANDEMBRY® (garadacimab) as Once-Monthly Treatment for Hereditary Angioedema (HAE)
August 8, 2025
U.S. Food and Drug Administration Approves CSL's ANDEMBRY® (garadacimab-gxii), the Only Prophylactic Hereditary Angioedema (HAE) Treatmen...
June 16, 2025
England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy
May 23, 2025
CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy
April 29, 2025
CSL Receives Approval in Japan for ANDEMBRY® (garadacimab) Subcutaneous (S.C.) Injection 200mg Pens, a Novel Human Anti-Activated Factor ...
February 20, 2025
CSL Statutory Accounts for the Half Year Ended 31 Dec 2024
February 10, 2025
Results Presentation
August 12, 2024
Results Announcement
August 12, 2024
Full Year Statutory Accounts for 30 June 2024
August 12, 2024
Half Year Results Investor Presentation
February 12, 2024
Statutory Accounts for the Half Year Ended 31 December 2023
February 12, 2024
Half Year Results Announcement
February 12, 2024
Top-line Results from the Phase 3 AEGIS-II Trial
February 11, 2024